Silver Book Fact

Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections

Bressler N, Chang T, Fine J, Dolan C, et al. Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR. Ophthalmol. 2010; 117(4). http://www.aaojournal.org/article/S0161-6420(09)00981-6/abstract

Reference

Title
Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR
Publication
Ophthalmol
Publication Date
2010
Authors
Bressler N, Chang T, Fine J, Dolan C, et al.
Volume & Issue
Volume 117, Issue 4
Pages
747-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Economics of DR Treatment
    Laser treatment plus a VEGF inhibitor achieved an incremental cost-effectiveness ratio of $12,410 per quality adjusted life year in patients with DME.  
  • AMD risk reduction through diet
    A recent study indicated that 20% of AMD cases in the AREDS study would have been eliminated if the participants consumed diets with a dGI (dietary glycemic index) below the…  
  • The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but…  
  • Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients…  
  • The cost-effectiveness of detection and treatment of eye disease in diabetics is $3,190 per quality adjusted life year (QALY).